Article

Metagenomic and Metabolomic Correlates of Immunotherapy Response in Non-Small Cell Lung Cancer

2026-07-09

Abstract excerpt

<title>Abstract</title> <p> <bold>Background</bold> The gut microbiome may influence cancer treatment response, perhaps by immune system interactions, but studies are limited among non-small cell lung cancer (NSCLC) patients. We investigated associations of the pre-treatment gut microbiome and serum metabolome/lipidome with immune checkpoint inhibitor (ICI) response among patients with stage III-IV NSCLC. <bol...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 6d2aa705-a6b7-5ffb-b683-7905e5f2de8e
DOI: 10.21203/rs.3.rs-10107631/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Metagenomic and Metabolomic Correlates of Immunotherapy Response in Non-Small Cell Lung CancerDOI 10.21203/rs.3.rs-10107631/v1Read

Gut microbiome metabolites, molecular mimicry, and species-level variation drive long-term efficacy and adverse event outcomes in lung cancer survivorsSemantic proximity Read

Distinct Functional Metagenomic Markers Predict the Responsiveness to Anti-PD-1 Therapy in Chinese Non-Small Cell Lung Cancer PatientsSemantic proximity Read

Understanding Microbiome Effect on Immune Checkpoint Inhibition in Lung Cancer: Placing the Puzzle Pieces TogetherSemantic proximity Read

Gut Metatranscriptomics Based De Novo Assembly Reveals Microbial Signatures Predicting Immunotherapy outcomes in Non-Small Cell Lung CancerSemantic proximity Read

Microbiome and EGFR-mutant non-small cell lung cancer: a complex interplay.Semantic proximity Read

Gut microbial signature in lung cancer patients highlights specific taxa as predictors for durable clinical benefitSemantic proximity Read

Gut Microbiota a Novel Source of Biomarkers for Immunotherapy in Non-small Cell Lung Cancer (NSCLC)Semantic proximity Read

Dysbiosis in the Gut Microbiome of Pembrolizumab‐Treated Non‐Small Lung Cancer Patients Compared to Healthy Controls Characterized Through Opportunistic SamplingSemantic proximity Read

Exploring Gut Microbiome in Predicting the Efficacy of Immunotherapy in Non-Small Cell Lung CancerSemantic proximity Read

Monitoring and Modulating Diet and Gut Microbes to Enhance Response and Reduce Toxicity to Cancer TreatmentSemantic proximity Read

Gut Microbiome Diversity and Specific Composition During Immunotherapy in Japanese Responders with Non-Small Cell Lung CancerSemantic proximity Read

Gut microbiome and response to checkpoint inhibitors in non-small cell lung cancer—A reviewSemantic proximity Read